Herbal medicines are considered health food in many Western nations. This perception is due to the slow action and low efficacy of herbal medicine. JBNI scientists have formulated fast acting, safe, all-natural, herbal remedies that are as effective as commercial pharmaceutical drugs. JBNI scientists have been developing naturaceuticals for decades.
In 1974, the scientists of JBNI (then DHI) succeeded in developing all natural NSAID's (Non-Steroidal Anti-Inflammatory Drugs). While developing non-anaphylactic NSAIDs, they additionally succeeded in combining the strong anti-inflammatory function with antibacterial, antiviral, antifungal qualities. As a result, the natural Formula 15.1 became the first antibiotic that also eliminated fungal growth as well as inflammations.
In 1978, JBNI (then OMR) scientists further succeeded in formulating over 50 natural formulas.
In 1989, JBNI (then JJHC) succeeded in further improving Formula 15.1 by strengthening its anti-inflammatory action and pain killing capabilities. This improvement marked the new Formula 15.3
In 1991, JBNI (then JJI) scientists collaborated with TSRA (Triple S Research Associates) in order to further improve the overall safety and efficacy of its formulas. All of JBNI’s formulas were created to adhere to a safety standard far exceeding any existing regulations. As a result, JBNI’s herbal formulas yielding zero side effects with a single dose at 1/500 -1/100 of body weight. Many formulas were also tested against metastatic breast cancer (closely related to lung cancer), colorectal cancer, and skin cancer.
While JBNI and TSRA scientists strived to set new industrial standards, they discovered that the FDA had not yet set any requirements limiting heavy metal concentrations in food products. FDA scientists have since developed new standards on heavy metal, herbicide, and pesticide content based in part due to data from TSRA and JBNI scientists.
In 1993, JBNI (then JJI) began distributing nutritional health supplements exclusively to licensed physicians in the USA, which included MDs, DOs, LAcs and DCs. This decision was implemented as part of a long-term clinical observation strategy.
Since 2001, JBNI (then JJI) scientists have intensified their research in the fields of genomics, genetics, DNA, and proteomics. Together with IDD, CTRC, Beckman, Cyphergen, Luminex, Millipore, and Panomics, JBNI scientists have succeeded in identifying specific biomarkers used to forecast many types of cancer even decades before onset. JBNI scientists, together with IDD, CTRC, and CPC, have since led their peers in cancer prevention studies ever since. Abstracts documenting their collaboration are featured annually in AACR, NIH, NCI, and EORTC conventions.
In 2004, JBNI's “Azmazin,” received an IND (Investigational New Drug) number from the FDA as an asthma drug. It is anticipated to become the first natural drug, for asthma, approved by the FDA. Once completed, JBNI plans to apply for drug approval for each of its products.
In 2007, following three decades of careful observation, JBNI has made a select group of its products available to the public. These products are sold as nutritional supplements.
